Microba Life Sciences joins renowned Microbiome Therapeutics Innovation Group to drive life-saving therapeutics forward
Announcement posted by Microba Life Sciences 23 Feb 2021
AUSTRALIA - Leading biotech Microba Life Sciences has joined the ranks of prominent microbiome therapeutic, biopharmaceutical and bioscience companies as a new member of the Microbiome Therapeutics Innovation Group (MTIG).
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission of accelerating microbiome therapeutic development to advance medicine.
The addition of Microba brings MTIG’s membership to six companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products, as well as a new voice in Microba’s CEO Blake Wills as a new Director of MTIG’s Board.
A leader in gut microbiome analysis and precision microbiome science, Microba’s expertise in combining accurate measurement of the gut microbiome with a human-first, data-driven approach to therapeutic discovery is being used to develop microbiome-derived treatments as new solutions to human health problems.
Joining other members Seres Therapeutics, Rebiotix, Siolta Therapeutics, Takeda and Vedanta Biosciences, Microba will add to the collective voice of the group which aims to address unmet clinical needs, improve clinical outcomes and reduce healthcare costs.
Leveraging the status of the human microbiome as a new frontier in medical innovation, MTIG is an independent coalition of companies lending their voice to research and development of FDA-approved microbiome therapeutics and microbiome-based products.
“At Microba, our mission is to develop life-enhancing therapeutics to progress medicine by harnessing the microbiome as a rich source of novel therapeutics,” said Blake Wills, Microba CEO.
“Our core belief is that comprehensive and precise measurement of the human gut microbiome and our unique approach to genome-directed isolation are integral in driving new opportunities.”
Chairman of MTIG, Dr Ken Blount, PhD, said that Microba’s addition to MTIG would assist in their mission to advance health globally through innovative microbiome therapeutics.
“Microba Life Sciences brings a unique viewpoint as a pre-clinical biotech utilizing an innovative, data-focused approach to identifying therapeutic discoveries,” he said.
“We welcome their efforts as we seek to advance the regulatory field for microbiome therapeutics.”